A Randomised, Cross-over Study to Evaluate Efficacy and Tolerability of FLX-787 in Patients with Multiple Sclerosis spasticity and spasms/cramps
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs FLX 787 (Primary)
- Indications Cramp; Multiple sclerosis; Spasm
- Focus Therapeutic Use
- Acronyms Flex201
- Sponsors Flex Pharma
- 07 Mar 2018 According to Flex Pharma media release, the Company expects to report topline results from this study by the end of the first quarter of 2018.
- 19 Jan 2017 Prortocol amendment as per Australian New Zealand Clinical Trials Registry;washout period extended,enrollment ctiteria added,and patient number changed to 80
- 19 Jan 2017 Planned number of patients changed from 50 to 80.